What Tregs eat makes them strong and vulnerable: a new metabolic checkpoint for cancer immunotherapy research

Join us for our eSeminar presented by Dr. Ping-Chih Ho to learn about Agilent Cell Analysis applications in cancer immunotherapy research.

The aberrant accumulation of regulatory T cells (Tregs) in tumors promotes immunosuppressive features of the tumor microenvironment (TME). Although depleting Tregs unleashes antitumor immunity and reprograms the immune status of the TME, the therapeutic potential of Treg-targeting is largely compromised due to autoimmunity induced by systemic loss of Tregs. Given that Tregs reside in different locations where they contain distinct nutrient composition, metabolic adaptation should be engaged by Tregs to support their tissue retention and tissue-dependent behavior. This talk will discuss how we can selectively demolish intramural Tregs by targeting unique metabolic preference of intratumoral Tregs and how this approach can be utilized for cancer research.

In this webinar we will discuss

  • Metabolic adaptation supports unique metabolic programs in intratumoral Tregs.
  • Metabolic vulnerability of intramural Tregs and its impact for cancer research.
  • Synergistic anti-tumor responses of PD-1 blockade with metabolic targeting against intramural Tregs.

Tuesday, June 25, 2019

07:00 PDT (Los Angeles)
10:00 EDT (New York)
15:00 GMT (London)

Presented by:

Ping-Chih Ho, PhD
Assistant Professor
Department of Fundamental Oncology, University of Lausanne
Ludwig Center for Cancer Research

  Register now  

For Research Use Only. Not for use in diagnostic procedures.

©2018 Agilent Technologies